Author
@adamfeuerstein adamfeuerstein
grade Ax.com/adamfeuerstein ↗
Veteran biotech journalist decoding clinical data and calling out hype
Breaks biotech/pharma news and delivers skeptical, data-lite
trader score
-1.03
hit rate
40%
mean α
-0.45%
signals 14d
34
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 40% hit rate, -0.45% mean alpha, trader score -1.03. Their last-14d mentions, direction-adjusted, have moved +2.8% since posting (mean over 24 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | · | @adamfeuerstein | · | Argues an unnamed drug should not have been approved and endorses Europe's rejection. | · | tweet ↗ |
| 2026-10-15 | ROIV | @adamfeuerstein | -0.10 | Quotes ROIV's CEO criticizing investor-driven degrossing as harmful noise for the biotech industry. | · | tweet ↗ |
| 2026-10-15 | MRK | @adamfeuerstein | +0.20 | Reads relaxed and confident executive body language as mildly positive ahead of an ESMO presentation. | +0.1% | tweet ↗ |
| 2026-10-15 | MRNA | @adamfeuerstein | +0.20 | Reads relaxed and confident executive body language as mildly positive ahead of an ESMO presentation. | -15.4% | tweet ↗ |
| 2026-10-15 | JNJ | @adamfeuerstein | +0.40 | Argues JNJ's Inlexzo already leads Anktiva and is pursuing the same bladder-cancer expansion opportunity. | +4.2% | tweet ↗ |
| 2026-10-15 | IBRX | @adamfeuerstein | -0.50 | Argues JNJ's Inlexzo already leads Anktiva and is pursuing the same bladder-cancer expansion opportunity. | -17.8% | tweet ↗ |
| 2026-10-15 | JNJ | @adamfeuerstein | +0.20 | Prior commentary warned that an IBRX regulatory shortcut could also benefit JNJ's competing drug. | +4.2% | tweet ↗ |
| 2026-10-15 | IBRX | @adamfeuerstein | -0.35 | Prior commentary warned that an IBRX regulatory shortcut could also benefit JNJ's competing drug. | -17.8% | tweet ↗ |
| 2026-10-15 | JNJ | @adamfeuerstein | +0.25 | FDA approved IBRX's Anktiva for papillary NMIBC and invited JNJ to seek an Inlexzo label expansion. | +4.2% | tweet ↗ |
| 2026-10-15 | IBRX | @adamfeuerstein | +0.50 | FDA approved IBRX's Anktiva for papillary NMIBC and invited JNJ to seek an Inlexzo label expansion. | -17.8% | tweet ↗ |
| 2026-10-14 | · | @adamfeuerstein | · | Metaphorically characterizes biotech investing as highly destructive to participants. | · | tweet ↗ |
| 2026-10-13 | NBIX | @adamfeuerstein | -0.65 | FOIA case reports link Vykat to seven deaths and 100 hospitalizations, with experts urging withdrawal. | +5.6% | tweet ↗ |
| 2026-10-13 | NBIX | @adamfeuerstein | +0.15 | Reports Neurocrine's defense of Vykat's benefit-risk profile amid safety concerns. | +5.6% | tweet ↗ |
| 2026-10-12 | VKTX | @adamfeuerstein | -0.20 | References chief commercial officer Aubuchon's exit and notes no visible sell-side response. | -13.9% | tweet ↗ |
| 2026-10-12 | VKTX | @adamfeuerstein | -0.20 | Reports Viking's chief commercial officer departed without a company statement or 8-K filing. | -13.9% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.